NCT05297734

Brief Summary

This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,996

participants targeted

Target at P75+ for not_applicable

Timeline
21mo left

Started Jun 2022

Longer than P75 for not_applicable

Geographic Reach
1 country

17 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress70%
Jun 2022Feb 2028

First Submitted

Initial submission to the registry

March 17, 2022

Completed
11 days until next milestone

First Posted

Study publicly available on registry

March 28, 2022

Completed
3 months until next milestone

Study Start

First participant enrolled

June 24, 2022

Completed
5.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2028

Expected
28 days until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2028

Last Updated

April 30, 2026

Status Verified

April 1, 2026

Enrollment Period

5.6 years

First QC Date

March 17, 2022

Last Update Submit

April 24, 2026

Conditions

Keywords

CarcinomaLung NeoplasmsCarcinoma, Non-Small-Cell LungMelanomaPancreatic NeoplasmsSarcomaOvarian NeoplasmsCarcinoma, Ovarian EpithelialStomach NeoplasmsGlioblastomaRectal NeoplasmsColonic NeoplasmsEsophageal NeoplasmsBreast NeoplasmsCarcinoma, Renal CellSkin NeoplasmsSmall Cell Lung CarcinomaOsteosarcomaMyelodysplastic SyndromesDisease ProgressionNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteLung DiseasesRespiratory Tract DiseasesUrogenital NeoplasmsCarcinoma, Bronchogenic

Outcome Measures

Primary Outcomes (1)

  • Change in health-related quality of life as assessed by the Functional Assessment of Cancer Therapy (FACT-G).

    Each patient will receive a health-related quality of life survey (FACT-G) at baseline, 3 months, 6 months, and 12 months.

    Change in health-related quality of life from baseline to 3 months

Secondary Outcomes (10)

  • Change in health-related quality of life as assessed by the Functional Assessment of Cancer Therapy (FACT-G).

    Change in health-related quality of life from baseline to 6, and 12 months

  • Change in patient activation using the Patient Activation Measure (PAM-13).

    Change in patient activation from baseline to 3, 6, and 12 months

  • Change in satisfaction with care using the Consumer Assessment of Health Care (Providers and Systems (CAHPS) Cancer Care Survey Questions #39 and #42.

    Change in satisfaction with care from baseline to 3, 6, and 12 months

  • Change in satisfaction with decision using the Satisfaction with Decision Scale (SWD)

    Change in satisfaction with decision from baseline to 3, 6, and 12 months

  • Palliative Care Use (Self-reported and Chart Review)

    3, 6, and 12 months after patient enrollment

  • +5 more secondary outcomes

Other Outcomes (2)

  • Time Toxicity

    3, 6, and 12 months after patient enrollment

  • Financial Toxicity

    3, 6, and 12 months after patient enrollment

Study Arms (2)

Technology-based supportive cancer care

ACTIVE COMPARATOR

Patients receive educational materials to assist with advance care planning and symptom management through a technology-based supportive cancer care weekly during months 1-4 and every other week during months 5-12.

Other: Receive technology-based supportive cancer care

Redesigned team-based supportive cancer care

EXPERIMENTAL

Patients are paired with a health educator who will discuss the same educational materials from ARM A either in person or by telephone discussions weekly during months 1-4 and every other week during months 5-12.

Behavioral: Receive redesigned team-based supportive cancer care

Interventions

All participants will receive an electronic health record message or email with standardized information provided regarding advance care planning and symptom management.

Also known as: Technology-based SCC approach
Technology-based supportive cancer care

Lay Health Workers will meet with 1:1 with participants over 12 months to discuss advance care planning, surrogate decision-makers, advance directives and physician orders for life sustaining treatment.

Also known as: Patients Activated in Cancer care through Teams (PACT), Redesigned SCC team-based approach
Redesigned team-based supportive cancer care

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Newly diagnosed patients with solid tumor cancer diagnosis or recurrence of the disease.
  • Patients must have the ability to understand and willingness to provide verbal consent.
  • Participants must speak English, Spanish, Chinese, or Vietnamese.

You may not qualify if:

  • Inability to consent to the study
  • Plans to change oncologist within 12 months
  • Employed by the practice site
  • Patients who anticipate moving from the area within 12 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (17)

University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States

RECRUITING

University of South Alabama

Mobile, Alabama, 36688, United States

RECRUITING

Beckman Research Institute of City of Hope

Duarte, California, 91010, United States

RECRUITING

VA Medical Center, Fresno

Fresno, California, 93703, United States

RECRUITING

Santa Clara Valley Medical Center

Fruitdale, California, 95128, United States

RECRUITING

St Jude Heritage Medical Group

Fullerton, California, 92835, United States

RECRUITING

Oncology Institute for Hope and Innovation

Los Angeles, California, 90017, United States

RECRUITING

Sacramento VA Medical Center - VA Northern California Health Care System

Mather, California, 95655, United States

ACTIVE NOT RECRUITING

Pacific Cancer Care

Monterey, California, 93940, United States

ACTIVE NOT RECRUITING

VA Palo Alto

Palo Alto, California, 94305, United States

ACTIVE NOT RECRUITING

Zuckerberg San Francisco General

San Francisco, California, 94110, United States

RECRUITING

Kaiser Foundation Research Institute

San Francisco, California, 94115, United States

RECRUITING

University of San Francisco

San Francisco, California, 94117, United States

RECRUITING

San Francisco VA Medical Center

San Francisco, California, 94121, United States

ACTIVE NOT RECRUITING

Spark M. Matsunaga VA Medical Center

Honolulu, Hawaii, 96819, United States

RECRUITING

North Las Vegas VA Medical Center

Las Vegas, Nevada, 89086, United States

ACTIVE NOT RECRUITING

George E. Wahlen Department of Veterans Affairs Medical Center

Salt Lake City, Utah, 84148, United States

RECRUITING

MeSH Terms

Conditions

DeathNeoplasmsCarcinomaLung NeoplasmsCarcinoma, Non-Small-Cell LungMelanomaPancreatic NeoplasmsSarcomaOvarian NeoplasmsCarcinoma, Ovarian EpithelialStomach NeoplasmsGlioblastomaRectal NeoplasmsColonic NeoplasmsEsophageal NeoplasmsBreast NeoplasmsCarcinoma, Renal CellSkin NeoplasmsSmall Cell Lung CarcinomaOsteosarcomaMyelodysplastic SyndromesDisease ProgressionNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteLung DiseasesRespiratory Tract DiseasesUrogenital NeoplasmsCarcinoma, Bronchogenic

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsBronchial NeoplasmsNeuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms, Nerve TissueNevi and MelanomasSkin DiseasesSkin and Connective Tissue DiseasesDigestive System NeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System DiseasesNeoplasms, Connective and Soft TissueOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, FemaleGenital DiseasesGonadal DisordersGastrointestinal NeoplasmsGastrointestinal DiseasesStomach DiseasesAstrocytomaGliomaNeoplasms, NeuroepithelialColorectal NeoplasmsIntestinal NeoplasmsIntestinal DiseasesRectal DiseasesColonic DiseasesHead and Neck NeoplasmsEsophageal DiseasesBreast DiseasesAdenocarcinomaKidney NeoplasmsUrologic NeoplasmsKidney DiseasesUrologic DiseasesMale Urogenital DiseasesNeoplasms, Bone TissueNeoplasms, Connective TissueBone Marrow DiseasesHematologic DiseasesHemic and Lymphatic DiseasesDisease Attributes

Central Study Contacts

Manali I Patel, MD MPH MS

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Model Details: Cluster Randomized Controlled Trial among 26 clinics
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Medicine

Study Record Dates

First Submitted

March 17, 2022

First Posted

March 28, 2022

Study Start

June 24, 2022

Primary Completion (Estimated)

January 31, 2028

Study Completion (Estimated)

February 28, 2028

Last Updated

April 30, 2026

Record last verified: 2026-04

Locations